Alkem Laboratories Q1 results show revenue up from 2972.27 crores to 3033.56 crores, a 2.06% increase in growth. EPS rise from ₹5.94 to ₹23.98, up by 303.70%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Alkem Laboratories shared its Q1 results on Thursday. They earned 3033.56 crores in revenue this quarter, but that’s more than the 2972.27 crores they made last quarter. The company’s growth increased by 2.06 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 286.73 crores, up from 70.98 crores in the previous quarter. Their quarter-to-quarter growth increased by 303.96 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹23.98, which is an increase of 303.70% from the ₹5.94 EPS in the previous quarter.
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 3033.56 crores this year (2023), which is 15.44 percent higher than last year’s total revenue of 2627.79 crores.
This year’s PAT (Profit After Tax) is 286.73 crores, which is also 124.64% higher than last year’s PAT of 127.64 crores.
The EPS (Earnings Per Share) for this year is ₹23.98, which is 124.53% more than the EPS of ₹10.68 earned last year.
Alkem Laboratories Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Alkem Laboratories:
Headquartered in Mumbai, Alkem Laboratories Ltd stands as an eminent Indian multinational pharmaceutical corporation. The company specializes in the production and distribution of pharmaceutical generics, formulations, and nutraceuticals, catering to both domestic and international markets.
Download the Full PDF of Alkem Laboratories Q1 Results: Click Here
For more of the Latest News, Click Here
